Activity, folding, misfolding, and aggregation in vitro of the naturally occurring human tissue factor mutant R200W.
Tissue factor (TF), a small transmembrane receptor, binds factor VIIa (FVIIa), and the formed complex initiates blood coagulation by proteolytic activation of substrate factors IX and X. A naturally occurring mutation in the human TF gene was recently reported, where a single-base substitution results in an R200W mutation in the TF extracellular domain [Zawadzki, C., Preudhomme, C., Gaveriaux, V., Amouyel, P., and Jude, B. (2002) Thromb. Haemost. 87, 540-541]. This mutation appears to be associated with low monocyte TF expression and may protect against thrombosis but has not been associated with any pathological condition, and individuals who present the heterozygous trait appear healthy. Here, we report the activity, folding, and aggregation behavior of the R200W mutant of the 219-residue soluble extracellular domain of TF (sTF(R200W)) compared to that of the wild-type protein (sTF(wt)). No differences in stability or FVIIa cofactor activity but an impaired ability to promote FX activation at physiological conditions between the sTF(R200W) mutant and sTF(wt) were evident. Increased binding of 1-anilino-8-naphthalene-sulfonic acid (ANS) to sTF(R200W) indicated a population of partially folded intermediates during denaturation. sTF(R200W) showed a dramatically increased propensity for aggregate formation compared to sTF(wt) at mildly acidic pHs, with an increased rate of aggregation during conditions, promoting the intermediate state. The lowered pH resistance could explain the loss of sTF(R200W) in vivo because of aggregation of the mutant. The intrinsic structure of the sTF aggregates appears reminiscent of amyloid fibrils, as revealed by thioflavin T fluorescence, atomic force microscopy, and transmission electron microscopy. We conclude that the lowered activity for FX activation and the propensity of the mutant protein to misfold and aggregate will both contribute to decreased coagulation activity in TF(R200W) carriers, which could protect from thrombotic disease.
Wiréhn
Jimmy
J
IFM-Department of Chemistry, Linköping University, 581 83 Linköping, Sweden.
Carlsson
Karin
K
Herland
Anna
A
Persson
Egon
E
Carlsson
Uno
U
Svensson
Magdalena
M
Hammarström
Per
P
D000682:Amyloid / Q000235:genetics / Q000378:metabolism / Q000648:ultrastructure; D000817:Anilino Naphthalenesulfonates / Q000378:metabolism; D001120:Arginine / Q000235:genetics*; D052160:Benzothiazoles; D005110:Extracellular Space / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D015942:Factor VIIa / Q000378:metabolism; D006580:Genetic Carrier Screening; D006801:Humans; D007700:Kinetics; D009154:Mutation; D009391:Nephelometry and Turbidimetry; D011485:Protein Binding / Q000235:genetics; D011489:Protein Denaturation; D017510:Protein Folding; D013050:Spectrometry, Fluorescence; D013379:Substrate Specificity / Q000235:genetics; D013844:Thiazoles / Q000378:metabolism; D013925:Thromboplastin / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism / Q000648:ultrastructure; D014364:Tryptophan / Q000737:chemistry / Q000235:genetics*
D000682:Amyloid; D000817:Anilino Naphthalenesulfonates; D052160:Benzothiazoles; D013844:Thiazoles; C009462:thioflavin T; C027132:1-anilino-8-naphthalenesulfonate; D014364:Tryptophan; D013925:Thromboplastin; D001120:Arginine; D015942:Factor VIIa